Impact of diabetes mellitus on indeterminate results of the QuantiFERON TB Gold In-Tube test: A propensity score matching analysis

Hong-Joon Shin*, Tae-Ok Kim*, Hyung-Joo Oh, Ha-Young Park, Jin-Sun Chang, Seong Ahn, Yu-Il Kim, Sung-Chul Lim, Yong-Soo Kwon*

Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea

*These authors contributed equally to this work.
*yskwon@jnu.ac.kr

Abstract

Background

The sensitivity of interferon-gamma release assays (IGRAs) in the detection of Mycobacterium tuberculosis infection could be affected by conditions of immune dysregulation. For this reason, diabetes mellitus (DM) may increase the frequency of indeterminate results of IGRAs. However, there have been inconsistent reports of role of DM on indeterminate IGRA results.

Methods

We retrospectively reviewed all patients who underwent QuantiFERON-TB Gold In-Tube testing (QFT-GIT) at Chonnam National University Hospital. We collected the clinical and laboratory data of these patients.

Results

Of all 3,391 subjects, 1,265 (37.3%) had a positive QFT-GIT result, 266 (7.8%) had an indeterminate result, and 1,860 (54.9%) had a negative result. The mean age was 54.8 ± 18.1 years and 55.0% of the patients were male. There were 512 (15.1%) patients with DM. Multivariable analysis revealed that systemic corticosteroid use, tuberculosis, lymphocytopenia, low serum albumin, and high serum C-reactive protein (CRP) levels were significantly associated with indeterminate QFT-GIT results. However, DM was not associated with indeterminate QFT-GIT results (adjusted odds ratio, 0.98; 95% confidence interval, 0.69–1.41; P = 0.939). After propensity score matching, DM was not associated with indeterminate results of QFT-GIT.

Conclusion

In this large cohort study, DM does not affect the incidence of indeterminate results of QFT-GIT.
Introduction

Interferon-γ (IFN-γ) release assays (IGRAs) are immunologic tests that can help clinicians diagnose tuberculosis (TB) and latent *Mycobacterium tuberculosis* (*Mtb*) infection by demonstrating the immunologic response to *Mtb* antigens [1]. The QuantiFERON-TB Gold In-Tube test (QFT-GIT) is an enzyme-linked immunosorbent assay (ELISA) that quantifies the IFN-γ response of fresh whole blood to a cocktail of *Mtb* antigens (early secretory antigenic target-6 [ESAT-6], culture filtrate protein-10 [CFP-10], and TB7.7), and it has been used widely. However, indeterminate results could limit the usefulness of this test and cause confusion for clinicians in the diagnosis of *Mtb* infection. Moreover, the rate of indeterminate results is relatively high; a recent meta-analysis showed that the incidence of indeterminate QuantiFERON-TB Gold test results ranged from 3% to 21%. This included a pooled rate of 2.1%, which increased to 4.4% in immunosuppressed patients [2].

Diabetes mellitus (DM) is an important co-morbidity in patients with tuberculosis (TB) because it can increase the risk of active TB [3, 4], have severe clinical manifestations, and cause worse outcomes [5, 6]. DM can also cause dysregulation of the immune system, resulting in altered levels of cytokines and chemokines [7, 8]. However, there have been inconsistent reports of IFN-γ levels in response to *Mtb* in patients with TB and latent TB infection. Studies in patients with TB showed that those with DM had a higher response to a purified protein derivative from *Mtb* [9] and *Mtb* antigens [10], but no difference in the response to an *Mtb* sonicate [11] compared with patients without DM. However, another study in patients with latent TB infection showed that the response to *Mtb* antigens was decreased in patients with DM compared with that in patients without DM [12]. Furthermore, a recent study indicated that TB patients with DM were over 4 times more likely to have indeterminate QFT-GIT results using univariate analysis, although the effect was lost after adjusting for confounders [13]. In this study, we evaluated whether an indeterminate result of QFT-GIT is affected by DM.

Methods

Study population

We retrospectively reviewed all patients aged over 18 years who underwent QFT-GIT testing at Chonnam National University Hospital between January 2013 and December 2014.

Immunocompromised medical conditions

Immunocompromised patients were defined as those who had comorbidities, such as: DM, chemotherapy for an underlying malignancy at the time of QFT-GIT, solid organ transplant or bone marrow transplant, renal replacement therapy for chronic renal failure, human immunodeficiency virus (HIV) infection, and advanced liver cirrhosis of Child-Pugh class C. Patients receiving daily administration of immunosuppressive agents (at least 15 mg of prednisone per day for more than 1 month, or combination therapy with low dose corticosteroids and other immunosuppressive agents, including azathioprine, mycophenolate, methotrexate, cyclosporine, or cyclophosphamide) were also defined as immunocompromised. DM was defined by a history of DM with prior use of antidiabetic medications.

Diagnosis of TB

TB was diagnosed on the basis of *Mycobacterium tuberculosis* identification by culture or polymerase chain reaction from clinical specimens or clinical, radiological, or histological findings compatible with TB and responses to TB treatment.
Assessment of clinical and laboratory findings

Laboratory data included lymphocyte and platelet counts, hemoglobin, albumin, C-reactive protein (CRP), and serum glucose levels. HIV was detected using screening with an Architect HIV Ag/Ab Combo Kit (Abbott Laboratories, Abbot Park, IL, USA) to determine the presence of the HIV antibody and/or antigen. The results were confirmed using an additional HIV Western blot (HIV BLOT 2.2 Western Blot Assay, MP Diagnostics, Asia Pacific Pte Ltd., Singapore). Anemia was defined according to the World Health Organization (WHO) guidelines as a baseline hemoglobin level <13 g/dL in men or <12 g/dL in women [14]. Lymphocytopenia was defined as a blood lymphocyte count $<1.0 \times 10^9$/L.

QuantiFERON-TB Gold In-Tube test

The QFT-GIT test was performed according to the manufacturer’s instructions. Briefly, the test consisted of 3 blood collection tubes: a nil control tube (negative control: whole blood without antigens or mitogen), a mitogen control tube (positive control: whole blood with phytohemagglutinin), and a TB antigen tube (whole blood with a synthetic peptide cocktail simulating the Mtb-specific antigens, including ESAT-6, CFP-10, and TB7.7). The blood tubes were incubated for 20 hours at 37°C. The concentrations of IFN-$\gamma$ were measured using an ELISA, which was either performed manually or using an automated microplate processor (Evolis Twin Plus system; Bio-Rad Laboratories, Hercules, CA, USA).

Definitions of indeterminate result

The QFT-GIT results for each patient were interpreted according to the manufacturer’s criteria. Briefly, the QFT-GIT result was defined as positive if the IFN-$\gamma$ level of Nil was $\leq 8.0$ IU/mL and that of TB antigen minus Nil was $\geq 0.35$ IU/mL and $\geq 25\%$ of Nil value. A negative result was defined if the IFN-$\gamma$ level of Nil was $\leq 8.0$ IU/mL, that of Mitogen minus Nil was $\geq 0.5$ IU/mL, and that of TB antigen minus Nil was $< 0.35$ IU/mL or $< 25\%$ of Nil value. The results were reported as indeterminate if the IFN-$\gamma$ level of Nil was $\leq 8.0$ IU/mL, that of TB antigen minus Nil was $< 0.35$ IU/mL or $\geq 0.35$ IU/mL and $< 25\%$ of Nil value, and Mitogen minus Nil was $< 0.5$ IU/mL (positive control failure) or if the IFN-$\gamma$ level of Nil was $> 8.0$ IU/mL (negative control failure). Positive and negative results for QFT-GIT were combined into 1 variable termed “determinate”.

Statistical analysis

All data are expressed as mean or standard deviation or as numbers and percentages. The Pearson’s $\chi^2$ or Fisher’s exact tests were used for categorical variables to compare between determinate and indeterminate groups. The Student’s t-test were used for continuous variables to compare between determinate and indeterminate groups. To identify factors associated with indeterminate QFT-GIT results, logistic regression analysis was used in univariate analysis. Subsequently, multivariable logistic regression analysis was carried out, with inclusion of variables with P values of $<0.25$ in univariate analysis with enter method. We assessed the interactions between variables which were introduced the multivariable logistic regression model. There was significant interaction between DM and malignancy undergoing chemotherapy ($P = 0.038$). Therefore, we decided not to introduce the variable with malignancy undergoing chemotherapy to the final multivariable logistic regression model. We also measured the variance inflation factor (VIF) to identify the existence of collinearity in the variables of multivariable logistic regression analysis. We considered as a presence of collinearity if VIFs of variables were $> 5$. 

Impact of DM on indeterminate results of QFT-GIT
To evaluate influence of DM on indeterminate QFT-GIT result compared to determinate QFT-GIT result, we matched patients according to covariates of age, sex, rheumatic disease, malignancy undergoing chemotherapy, solid organ transplant, bone marrow transplant, chronic renal failure with renal replacement therapy, advanced liver cirrhosis, HIV infection, systemic corticosteroid or immunosuppressive agent use, diagnosis of TB, lymphocytopenia, anemia, and serum albumin and CRP levels. Propensity score matching was performed with one-to-one nearest neighbor matching without replacement. The caliper was 1.0 and the absolute standardized differences of the mean were within 0.1 for all variables. All subsequent analyses were performed in the matched sample, using methods appropriate for the analysis of matched data. The Paired t-test was used for continuous variables and the McNemar’s test was used for categorical variables to compare between DM and non-DM groups after matching [15].

All statistical analysis was performed using SPSS 21.0 (SPSS Inc., Chicago, IL). Propensity score matching was performed using IBM SPSS 21.0 and R version R2.14.2 (R Foundation for Statistical Computing, Vienna, Austria). P < 0.05 was considered statistically significant.

Ethics statement
The protocol of this study was approved by the Chonnam National University Hospital Institutional Review Board. Informed consent was waived because of retrospective nature of this study, and patient information was anonymized and de-identified prior to analysis. (IRB number, CNUH-2017-169).

Results

Patient characteristics
Fig 1 shows the flowchart of this study. From January 2013 to December 2014, 3,571 patients underwent QFT-GIT testing more than once. We excluded patients who were under 18 years old (n = 127) or who underwent QFT-GIT more than twice without consistent results (n = 53). Of all 3,391 patients, 1,265 (37.3%) had a positive QFT-GIT result, 266 (7.8%) had an indeterminate result, and 1,860 (54.9%) had a negative result.

The baseline characteristics of each group are presented in Table 1. The mean patient age was 54.8 ± 18.1 years and 1,864 patients (55.0%) were men. A total of 512 patients (15.1%) had DM and 441 patients (13.0%) were diagnosed with TB. Among them, 236 (53.5%) patients had pulmonary TB, 185 (42.0%) had extra-pulmonary TB, and 20 (4.5%) had both pulmonary and extra-pulmonary TB simultaneously. Seven hundred patients (20.6%) had lymphocytopenia, and 1,635 (48.2%) had anemia, according to the WHO guidelines. Less than 5% of the patients had experienced chronic renal failure with renal replacement therapy, had undergone solid organ or bone marrow transplant, had HIV infection or advanced liver cirrhosis, or had received systemic corticosteroids.

Factors associated with indeterminate QFT-GIT results compared with determinate results
Table 2 shows the results of the univariate and multivariable analyses of clinical factors associated with indeterminate results compared with determinate results of QFT-GIT. In univariate analysis with logistic regression analysis, the difference between the indeterminate and determinate results was statistically significant in patients who had DM, advanced liver cirrhosis, diagnosis of TB, lymphocytopenia, or anemia, or who received systemic corticosteroids. Significant differences in the mean total age, serum albumin, and CRP levels were also observed.
between patients with determinate and indeterminate QFT-GIT results. Multivariable analysis by logistic regression analysis revealed that systemic corticosteroid use, a diagnosis of TB, lymphocytopenia, lower serum albumin, and higher serum CRP levels were significantly associated with indeterminate QFT-GIT results. Collinearities were not observed among variables in the multivariable logistic regression analysis (VIFs < 2.1). In contrast, DM was no longer associated with indeterminate QFT-GIT results following multivariable analysis (adjusted odds ratio [OR], 0.98; 95% confidence interval, 0.69–1.41; P = 0.939).

Relationship between indeterminate QFT-GIT results and DM: Propensity score matching analysis

We performed propensity score matching analysis to evaluate influence of DM on indeterminate QFT-GIT result compared to determinate QFT-GIT result by calculating propensity scores using logistic regression. After matching, there were 962 matched DM-non-DM patients. There was no significant difference between DM and non-DM groups after matching with absolute standardized differences of the mean were within 0.1 for all variables in each group (Table 3). Fifty-eight patients (12.1%) of DM group had indeterminate QFT-GIT results, and 60 (12.5%) had indeterminate QFT-GIT results. Logistic regression analysis revealed that DM was not associated with an indeterminate QFT-GIT result (Table 4).

Discussion

This cohort study included 3,391 subjects, which, to our knowledge, makes it the largest to date to demonstrate a relationship between DM and indeterminate IGRA results. We found that DM was not associated with indeterminate QFT-GIT results.

Indeterminate IGRA results can be caused by either a high background response or a poor response to the positive control mitogen (low mitogen). However, most reports show that
indeterminate results of QFT-GIT result from low mitogen [16–19]. In a previous study conducted in our institution, it was reported that 93% of the indeterminate results were because of low mitogen, which is similar to the results of the present study [20]. Therefore, indeterminate results of QFT-GIT could be associated with immunosuppression [20–25]. In DM, dysfunctional innate and adaptive immune responses to Mtb have been reported, and this could increase the risk of active TB [7, 8]. Consequently, the IFN-γ response to the Mtb antigen may be affected in patients with DM. However, inconsistent results have been reported about this issue in TB or latent TB infection [9–12]. Variable sensitivity has been reported in QFT-GIT results among DM patients. Some studies have reported the high sensitivity of QFT-GIT in TB patients with DM [26–28]; however, a recent study reported the low sensitivity of this test in TB patients with DM [29]. In TB patients with DM, it also unclear if DM affects the incidence of indeterminate QFT-GIT results. Some studies have shown that DM was not a risk factor for indeterminate QFT-GIT results [20, 22, 23]. However, these studies had fewer than 700 enrolled patients, among whom there were fewer than 70 DM patients. Moreover, some studies focused on specific populations, such as immunocompromised patients and those with rheumatic diseases [20, 22]. A recent, large multicenter study that included our institution enrolled 1,264 patients with active TB and 203 TB patients with DM; it showed that DM was a risk factor for indeterminate QFT-GIT results (OR, 2.58; 95% CI, 1.20–5.54) [25]. However, in

| Variables                                        | Total (n = 3,391) |
|-------------------------------------------------|------------------|
| Age (years)                                     | 54.8 ± 18.1      |
| Male                                            | 1,864 (55.0%)    |
| IGRA results                                    |                  |
| • Positive                                      | 1,265 (37.3%)    |
| • Negative                                      | 1,860 (54.9%)    |
| • Indeterminate                                 | 266 (7.8%)       |
| Diabetes mellitus                               | 512 (15.1%)      |
| Chronic renal failure with renal replacement therapy | 122 (3.6%)      |
| Rheumatic disease                               | 486 (14.3%)      |
| Malignancy undergoing chemotherapy              | 265 (7.8%)       |
| Solid organ transplant                          | 29 (0.9%)        |
| Bone marrow transplant                          | 25 (0.7%)        |
| Human immunodeficiency virus infection          | 96 (2.8%)        |
| Immunosuppressive agent use                     | 233 (6.9%)       |
| Advanced liver cirrhosis                        | 76 (2.2%)        |
| Systemic corticosteroid use                     | 143 (4.2%)       |
| Diagnosis of tuberculosis                       | 441 (13.0%)      |
| • Pulmonary tuberculosis                        | 236 (53.5%)      |
| • Extrapulmonary tuberculosis                   | 185 (42.0%)      |
| • Pulmonary and extrapulmonary tuberculosis     | 20 (4.5%)        |
| Lymphocytopenia                                 | 700 (20.6%)      |
| Anemia                                          | 1,635 (48.2%)    |
| Glucose (mg/dL)                                 | 123.2 ± 53.8     |
| Albumin (g/dL)                                  | 3.8 ± 0.7        |
| C-reactive protein (mg/dL)                      | 3.7 ± 6.0        |

Data are expressed as number (percentage) or mean ± standard deviation.
IGRA: interferon-gamma release assay

https://doi.org/10.1371/journal.pone.0181887.t001
### Table 2. Comparison between the determinate and indeterminate QFT-GIT result groups using logistic regression analysis.

| Variables                        | Determinate | Indeterminate | Univariate OR 95% CI | P adjusted OR 95% CI | P     |
|----------------------------------|-------------|---------------|----------------------|----------------------|-------|
| Age (years)                      | 54.3 ± 18.0 | 61.0 ± 17.3   | 1.0 1.0–1.0          | <0.000 1.0           | 0.693 |
| Male                             | 1,722 (55.1%) | 142 (53.4%)   | 0.9 0.7–1.2          | 0.588                |       |
| Diabetes mellitus                | 451 (14.4%) | 61 (22.9%)    | 1.7 1.3–2.3          | <0.000 0.9           | 0.6–1.4 0.939 |
| Chronic renal failure with RRT  | 108 (3.5%)  | 14 (5.3%)     | 1.5 0.8–2.7          | 0.132 0.9            | 0.5–1.8 0.945 |
| Rheumatic disease                | 448 (14.3%) | 38 (14.3%)    | 0.9 0.6–1.4          | 0.982                |       |
| Malignancy undergoing chemotherapy| 238 (7.6%) | 27 (10.2%)    | 1.3 0.9–2.0          | 0.141                |       |
| Solid organ transplantation       | 27 (0.9%)   | 2 (0.8%)      | 0.8 0.2–3.6          | 0.849                |       |
| Bone marrow transplantation       | 22 (0.7%)   | 3 (1.1%)      | 1.6 0.4–5.4          | 0.442                |       |
| HIV infection                    | 91 (2.9%)   | 5 (1.9%)      | 0.6 0.2–1.5          | 0.639                |       |
| Immunosuppressive agent use      | 216 (6.9%)  | 17 (6.4%)     | 0.9 0.5–1.5          | 0.919                |       |
| Advanced liver cirrhosis         | 65 (2.1%)   | 11 (4.1%)     | 2.0 1.0–3.8          | 0.033 0.9            | 0.4–2.0 0.988 |
| Systemic corticosteroid use      | 125 (4.0%)  | 18 (6.8%)     | 1.7 1.0–2.9          | 0.033 1.8            | 1.0–3.2 0.045 |
| Diagnosis of tuberculosis        | 424 (13.6%) | 17 (6.8%)     | 1.1 1.0–2.9          | 0.001 2.4            | 1.8–3.3 <0.000 |
| Lymphocytopenia                  | 564 (18.3%) | 136 (51.1%)   | 4.7 3.6–6.1          | <0.000 2.4           | 1.8–3.3 <0.000 |
| Anemia                           | 1,426 (46.2%) | 209 (78.6%)  | 4.2 3.1–5.7          | <0.000 1.1           | 0.7–1.6 0.448 |
| Albumin (g/dL)                   | 3.8 ± 0.7   | 3.0 ± 0.7     | 0.2 0.2–0.3          | <0.000 0.3           | 0.2–0.4 <0.000 |
| C-reactive protein (mg/dL)       | 3.1 ± 5.1   | 10.9 ± 9.9    | 1.1 1.1–1.2          | <0.000 1.0           | 1.0–1.1 <0.000 |

Data are expressed as number (percentage) or mean ± standard deviation.

QFT-GIT, QuantiFERON-TB Gold In-Tube test; OR, odds ratio; CI, confidence interval; RRT, renal replacement therapy; HIV, human immunodeficiency virus.

### Table 3. Patient characteristics before and after propensity score matching.

| Variables                        | Overall cases | Propensity score-matched pairs |
|----------------------------------|---------------|--------------------------------|
|                                  | Non-diabetes  | Diabetes | P  | Non-Diabetes  | Diabetes | P  |
|                                  | n = 2,879     | n = 512  |    | n = 481      | n = 481  |    |
| Age (years)                      | 53.0 ± 18.3   | 64.7 ± 12.9 | <0.000 | 66.0 ± 14.2  | 65.0 ± 12.8 | 0.085 |
| Male                             | 1,553 (53.9%) | 311 (60.7%) | 0.004 | 282 (58.6%)  | 294 (61.1%) | 0.454 |
| Chronic renal failure with RRT  | 67 (2.3%)     | 55 (10.7%) | <0.000 | 34 (7.1%)   | 44 (9.1%)  | 0.100 |
| Rheumatic disease                | 435 (15.1%)   | 51 (10.0%) | 0.002 | 55 (11.4%)  | 50 (10.4%)  | 0.682 |
| Malignancy receiving chemotherapy| 221 (7.7%)    | 44 (8.6%)  | 0.475 | 42 (8.7%)   | 43 (8.9%)  | 1.000 |
| Solid organ transplant           | 19 (0.7%)     | 10 (2.0%)  | 0.008 | 7 (1.5%)    | 7 (1.5%)   | 1.000 |
| Bone marrow transplant           | 20 (0.7%)     | 5 (1.0%)   | 0.571 | 2 (0.4%)    | 5 (1.0%)   | 0.453 |
| Advanced liver cirrhosis         | 53 (1.8%)     | 23 (4.5%)  | 0.001 | 22 (4.6%)   | 22 (4.6%)  | 1.000 |
| HIV infection                    | 88 (3.1%)     | 8 (1.6%)   | 0.060 | 5 (1.0%)    | 6 (1.2%)   | 1.000 |
| Immunosuppressive agent use      | 212 (7.4%)    | 21 (4.1%)  | 0.006 | 19 (4.0%)   | 21 (4.4%)  | 0.871 |
| Systemic corticosteroids use     | 127 (4.4%)    | 16 (3.1%)  | 0.232 | 10 (2.1%)   | 15 (3.1%)  | 0.424 |
| Diagnosis of tuberculosis        | 363 (12.6%)   | 78 (15.2%) | 0.116 | 520 (10.8%) | 70 (14.6%) | 0.099 |
| Lymphocytopenia                  | 563 (19.9%)   | 137 (26.9%) | <0.000 | 127 (26.4%) | 129 (26.8%) | 0.942 |
| Anemia                           | 1,273 (44.7%) | 362 (71.1%) | <0.000 | 331 (68.8%) | 343 (71.3%) | 0.290 |
| Albumin (g/dL)                   | 3.8 ± 0.7     | 3.4 ± 0.7  | <0.000 | 3.4 ± 0.7  | 3.4 ± 0.7  | 0.527 |
| C-reactive protein (mg/dL)       | 3.6 ± 5.8     | 5.5 ± 7.1  | <0.000 | 5.4 ± 6.7  | 5.5 ± 7.2  | 0.809 |

Data are expressed as number (percentage) or mean ± standard deviation.

The Pearson’s χ² or Fisher’s exact test was used for categorical variables and the Student’s t-test was used for continuous variables to compare between determinate and indeterminate groups in the overall cases.

RRT, renal replacement therapy; HIV, human immunodeficiency virus.

https://doi.org/10.1371/journal.pone.0181887.t002

https://doi.org/10.1371/journal.pone.0181887.t003
that study, the number of patients with indeterminate QFT-GIT results was only 40; this might cause over-fitting, and there may have been inter-dependent covariates in the multivariate analysis. Our study was strengthened by the large number of enrolled patients and the use of propensity score matching analysis. We enrolled 3,391 subjects to determine whether DM could increase indeterminate results in QFT-GIT. We also used propensity score matching to adjust possible variables affecting indeterminate IGRA results. After propensity score matching, DM was not associated with indeterminate IGRA results compared with determinate group.

In the present study, systemic corticosteroid use was associated with indeterminate IGRA results after multivariate analysis. However, other immunosuppressive conditions, including HIV infection, solid organ transplant, bone marrow transplant, advanced liver cirrhosis, systemic steroids, diagnosis of tuberculosis, lymphocytopenia, anemia, and albumin and C-reactive protein levels.

In conclusions, this observational study used propensity score-matched cohorts to demonstrate that DM does not affect the incidence of indeterminate results in IGRA testing.

Acknowledgments

This study was supported by the National Research Foundation of Korea funded by the Korean Government (Grant 2016R1D1A1B03931132).

Author Contributions

Conceptualization: Hong-Joon Shin, Tae-Ok Kim, Yong-Soo Kwon.

Data curation: Hong-Joon Shin, Tae-Ok Kim, Hyung-Joo Oh, Ha-Young Park, Jin-Sun Chang, Seong Ahn, Yu-Il Kim, Sung-Chul Lim, Yong-Soo Kwon.

Formal analysis: Hong-Joon Shin, Tae-Ok Kim, Hyung-Joo Oh, Ha-Young Park, Jin-Sun Chang, Seong Ahn, Yong-Soo Kwon.

Table 4. Relationship between indeterminate QFT-GIT results and diabetes mellitus using multivariable logistic regression and propensity score matched analysis.

| Model                        | No.    | OR   | 95% CI          | P value |
|------------------------------|--------|------|-----------------|---------|
| Unadjusted                   | 3,391  | 1.76 | 1.30–2.38       | < 0.000 |
| Multivariable \(^a\)         | 3,391  | 0.99 | 0.69–1.42       | 0.984   |
| Matched on propensity score  | 962    | 0.96 | 0.65–1.41       | 0.962   |

QFT-GIT, QuantiFERON-TB Gold In-Tube test; OR, odds ratio; CI, confidence interval.

\(^a\)Selected variables included age, sex, chronic renal failure with renal replacement therapy, advanced liver cirrhosis, systemic steroids, diagnosis of tuberculosis, lymphocytopenia, anemia, and albumin and C-reactive protein levels.

https://doi.org/10.1371/journal.pone.0181887.t004
**Funding acquisition**: Yong-Soo Kwon.

**Investigation**: Yong-Soo Kwon.

**Methodology**: Hong-Joon Shin, Tae-Ok Kim, Hyung-Joo Oh, Ha-Young Park, Jin-Sun Chang, Seong Ahn, Sung-Chul Lim, Yong-Soo Kwon.

**Project administration**: Hong-Joon Shin, Tae-Ok Kim, Yong-Soo Kwon.

**Resources**: Yong-Soo Kwon.

**Software**: Hong-Joon Shin, Tae-Ok Kim, Hyung-Joo Oh, Ha-Young Park, Jin-Sun Chang, Seong Ahn, Yong-Soo Kwon.

**Supervision**: Yu-Il Kim, Sung-Chul Lim, Yong-Soo Kwon.

**Validation**: Tae-Ok Kim, Yong-Soo Kwon.

**Visualization**: Yong-Soo Kwon.

**Writing – original draft**: Hong-Joon Shin, Tae-Ok Kim, Yong-Soo Kwon.

**Writing – review & editing**: Hong-Joon Shin, Tae-Ok Kim, Yu-Il Kim, Sung-Chul Lim, Yong-Soo Kwon.

**References**

1. Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis. 2016. https://doi.org/10.1093/cid/ciw694 PMID: 27932390.

2. Diel R, Lodenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. Chest. 2010; 137(4):952–68. https://doi.org/10.1378/chest.09-2350 PMID: 20022968.

3. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med. 2008; 5(7):e152. https://doi.org/10.1371/journal.pmed.0050152 PMID: 18630964; PubMed Central PMCID: PMC2459204.

4. Pizzol D, Di Gennaro F, Chhaganlal KD, Fabrizio C, Monno L, Putoto G, et al. Tuberculosis and diabetes: current state and future perspectives. Tropical medicine & international health: TM & IH. 2016; 21 (6):694–702. https://doi.org/10.1111/tmi.12704 PMID: 27102229.

5. Jimenez-Corona ME, Cruz-Hervert LP, Garcia-Garcia L, Ferreyra-Reyes L, Delgado-Sanchez G, Bobadilla-Del-Valle M, et al. Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes. Thorax. 2013; 68(3):214–20. https://doi.org/10.1136/thoraxjnl-2012-201756 PMID: 23250998; PubMed Central PMCID: PMC3585483.

6. Yoon YS, Jung JW, Jeon EJ, Seo H, Ryu YJ, Yim JJ, et al. The effect of diabetes control status on treatment response in pulmonary tuberculosis: a prospective study. Thorax. 2016. https://doi.org/10.1136/thoraxjnl-2015-207686 PMID: 27553224.

7. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011; 11 (2):98–107. https://doi.org/10.1038/nri2925 PMID: 21233852.

8. Restrepo BI, Schlesinger LS. Impact of diabetes on the natural history of tuberculosis. Diabetes Res Clin Pract. 2014; 106(2):191–9. https://doi.org/10.1016/j.diabres.2014.06.011 PMID: 25082309; PubMed Central PMCID: PMCPMC4260985.

9. Restrepo BI, Fisher-Hoch SP, Pino PA, Salinas A, Rahbar MH, Mora F, et al. Tuberculosis in poorly controlled type 2 diabetes: altered cytokine expression in peripheral white blood cells. Clin Infect Dis. 2008; 47(5):634–41. https://doi.org/10.1086/590565 PMID: 18652554; PubMed Central PMCID: PMCPMC2900313.

10. Kumar NP, Sridhar R, Banurekha VV, Jawahar MS, Nutman TB, Babu S. Expansion of pathogen-specific T-helper 1 and T-helper 17 cells in pulmonary tuberculosis with coincident type 2 diabetes mellitus. J Infect Dis. 2013; 208(5):739–48. https://doi.org/10.1093/infdis/jits241 PMID: 23715661; PubMed Central PMCID: PMCPMC3735309.

11. Stalenhoef JE, Alisjahbana B, Nielwan EJ, van der Ven-Jongekrijg J, Ottenhoff TH, van der Meer JW, et al. The role of interferon-gamma in the increased tuberculosis risk in type 2 diabetes mellitus. Eur J
Walsh MC, Camerlin AJ, Miles R, Pino P, Martinez P, Mora-Guzman F, et al. The sensitivity of interferon-gamma release assays for tuberculosis. J Clin Microbiol. 2008; 46(6):1935–40. https://doi.org/10.1128/JCM.02403-07 PMID: 18400912; PubMed Central PMCID: PMC2446885.

14. WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Available: http://www.who.int/vmnis/indicators/haemoglobin.pdf.

15. Austin PC. Comparing paired vs non-paired statistical methods of analyses when making inferences about absolute risk reductions in propensity-score matched samples. Statistics in medicine. 2011; 30(11):1292–301. https://doi.org/10.1002/sim.4200 PMID: 21337595; PubMed Central PMCID: PMC3110307.

16. Tebruegge M, de Graaf H, Sukhtankar P, Elikington P, Marshall B, Schuster H, et al. Extremes of age are associated with indeterminate QuantiFERON-TB gold assay results. J Clin Microbiol. 2014; 52(7):2694–7. https://doi.org/10.1128/JCM.00814-14 PMID: 24829238; PubMed Central PMCID: PMC4097868.

17. Hermansen T, Lilbaek T, Hansen AB, Andersen PH, Ravn P. QuantiFERON-TB Gold In-Tube test performance in Denmark. Tuberculosis (Edinb). 2014; 94(6):616–21. https://doi.org/10.1016/j.tube.2014.09.003 PMID: 25446289.

18. Fabre V, Shoham S, Page KR, Shah M. High Proportion of Indeterminate QuantiFERON-TB Gold In-Tube Results in an Inpatient Population Is Related to Host Factors and Preanalytical Steps. Open Forum Infect Dis. 2014; 1(2):ofu088. https://doi.org/10.1093/ofid/ofu088 PMID: 25734154; PubMed Central PMCID: PMC4281799.

19. Huang CT, Ruan SY, Tsai YJ, Kuo PH, Ku SC, Lee PL, et al. Effects of acute critical illnesses on the performance of interferon-gamma release assay. Sci Rep. 2016; 6:19972. https://doi.org/10.1038/srep19972 PMID: 26804497; PubMed Central PMCID: PMCPMC4726381.

20. Jung HJ, Kim TJ, Kim HS, Cho YN, Jin HM, Kim MJ, et al. Analysis of predictors influencing indeterminate whole-blood interferon-gamma release assay results in patients with rheumatic diseases. Rheumatol Int. 2014; 34(12):1711–20. https://doi.org/10.1007/s00296-014-3033-z PMID: 24816858.

21. Talati NJ, Seybold U, Humphrey B, Aina A, Tapia J, Weinfurter P, et al. Poor concordance between interferon-gamma release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals. BMC Infect Dis. 2009; 9:15. https://doi.org/10.1186/1471-2334-9-15 PMID: 19208218; PubMed Central PMCID: PMCPMC2649136.

22. Lange B, Vavra M, Kern WV, Wagner D. Indeterminate results of a tuberculosis-specific interferon-gamma release assay in immunocompromised patients. Eur Respir J. 2010; 35(6):1935–40. https://doi.org/10.1183/09031936.00226613 PMID: 24743963.

23. Hang NT, Lien LT, Kobayashi N, Shimbo T, Sakurada S, Thuong PH, et al. Analysis of factors lowering sensitivity of interferon-gamma release assay for tuberculosis. PLoS One. 2011; 6(8):e23806. https://doi.org/10.1371/journal.pone.0023806 PMID: 21886824; PubMed Central PMCID: PMCPMC3158775.

24. Leung TH, Yuen LC, Leung PC, Ho SS, Tam YL, et al. Predictive factors for indeterminate result on the Quantiferon-TB test in an intermediate tuberculosis-burden country. J Infect. 2011; 62(5):37–45. https://doi.org/10.1016/j.jinf.2011.03.004 PMID: 21414356.

25. Kwon YS, Kim YH, Jeon K, Jeong BH, Ryu YJ, Choi JC, et al. Factors that Predict Negative Results of QuantiFERON-TB Gold In-Tube Test in Patients with Culture-Confirmed Tuberculosis: A Multicenter Retrospective Cohort Study. PLoS One. 2015; 10(6):e0129792. https://doi.org/10.1371/journal.pone.0129792 PMID: 26070207; PubMed Central PMCID: PMC4466377.

26. Walsh MC, Camerlin AJ, Miles R, Pino P, Martinez P, Mora-Guzman F, et al. The sensitivity of interferon-gamma release assays is not compromised in tuberculosis patients with diabetes. Int J Tuberc Lung Dis. 2011; 15(2):179–84, i-iii. PMID: 21219678; PubMed Central PMCID: PMC3085021.

27. Jung JY, Lim JE, Lee HJ, Kim YM, Cho SN, Kim SK, et al. Questionable role of interferon-gamma assays for smear-negative pulmonary TB in immunocompromised patients. J Infect. 2012; 64(2):188–96. https://doi.org/10.1016/j.jinf.2011.09.008 PMID: 22120597.

28. Gan SH, KhinMar KW, Barkham TM, Koh CK, Shen L, Wang YT, et al. Interferon-gamma responses to Mycobacterium tuberculosis-specific antigens in diabetes mellitus. Eur Respir J. 2014; 44(3):805–8. https://doi.org/10.1183/09031936.0026613 PMID: 24743963.
29. Faurholt-Jepsen D, Aabye MG, Jensen AV, Range N, Praygod G, Jeremiah K, et al. Diabetes is associated with lower tuberculosis antigen-specific interferon gamma release in Tanzanian tuberculosis patients and non-tuberculosis controls. Scand J Infect Dis. 2014; 46(5):384–91. https://doi.org/10.3109/00365548.2014.885657 PMID: 24621055.